BeyondSpring, Inc. (NASDAQ:BYSI) is reporting second quarter financial results on Thursday 3rd September 2020, before market open.
According to analysts surveyed by Thomson Reuters, BYSI is expected to report 2Q20 loss of $ 0.57 per share.
For the full year, analysts anticipate loss of $ 2.39 per share bottom line.
Stock Performance
Shares of BeyondSpring, Inc. traded low $ -0.82 or -6.73 percent on Wednesday, reaching $ 11.37 with volume of 81.30 thousand shares. The stock opened down for the day at $ 12.13, after closing the previous day trading at $ 12.19.
According to the previous trading day, closing price of $ 12.19, representing a 29.96 % increase from the 52 week low of $ 9.38 and a 47 % decrease over the 52 week high of $ 23.00.
The company has a market capital of $ 346.71 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
BeyondSpring, Inc. will be hosting a conference call at 8:00 AM eastern time on 3rd September 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.beyondspringpharma.com
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The companys lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer.
